Metabotropic Glutamate Receptors Type 3 and 5 Feature the "NeuroTransmitter-type" of Glioblastoma: A Bioinformatic Approach.
| Autor: | Caridi M; Division of Hematology and Clinical Immunology, Department of Medicine, University of Perugia, Perugia, Italy., Alborghetti M; Department of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy., Pellicelli V; Internal Medicine, Sapienza University of Rome, Rome, Italy., Orlando R; Department of Physiology and Pharmacology, University Sapienza of Roma, Rome, Italy.; IRCCS Neuromed, Pozzilli, Italy., Pontieri FE; Department of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.; IRCCS Fondazione Santa Lucia, Rome, Italy., Battaglia G; Department of Physiology and Pharmacology, University Sapienza of Roma, Rome, Italy.; IRCCS Neuromed, Pozzilli, Italy., Arcella A; IRCCS Neuromed, Pozzilli, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current neuropharmacology [Curr Neuropharmacol] 2024; Vol. 22 (11), pp. 1923-1939. |
| DOI: | 10.2174/1570159X22666240320112926 |
| Abstrakt: | Background: Glioblastoma (GBM) represents an aggressive and common tumor of the central nervous system. The prognosis of GBM is poor, and despite a refined genetic and molecular characterization, pharmacological treatment is largely suboptimal. Objective: Contribute to defining a therapeutic line in GBM targeting the mGlu3 receptor in line with the principles of precision medicine. Methods: Here, we performed a computational analysis focused on the expression of type 3 and 5 metabotropic glutamate receptor subtypes (mGlu3 and mGlu5, respectively) in high- and low-grade gliomas. Results: The analysis allowed the identification of a particular high-grade glioma type, characterized by a high expression level of both receptor subtypes and by other markers of excitatory and inhibitory neurotransmission. This so-called neurotransmitter-GBM (NT-GBM) also shows a distinct immunological, metabolic, and vascularization gene signature. Conclusion: Our findings might lay the groundwork for a targeted therapy to be specifically applied to this putative novel type of GBM. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|